Education
About Us
Working with TipRanks
Follow Us
PharmaCyte Biotech (PMCB)
NASDAQ:PMCB
Total Valuation
PharmaCyte Biotech has a market cap or net worth of $8.31M. The enterprise value is ―.
Market Cap$8.31M
Enterprise Value―
Share Statistics
PharmaCyte Biotech has 6,863,699 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,863,699
Owned by Insiders―
Owned by Institutions1.21%
Financial Efficiency
PharmaCyte Biotech’s return on equity (ROE) is <0.01 and return on invested capital (ROIC) is -12.42%.
Return on Equity (ROE)<0.01
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)-12.42%
Return on Capital Employed (ROCE)-0.12
Revenue Per Employee0.00
Profits Per Employee166.88K
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of PharmaCyte Biotech is 60.86. PharmaCyte Biotech’s PEG ratio is 0.08.
PE Ratio60.86
PS Ratio0.00
PB Ratio0.51
Price to Fair Value0.51
Price to FCF-9.44
Price to Operating Cash Flow-9.44
PEG Ratio0.08
Income Statement
In the last 12 months, PharmaCyte Biotech had revenue of 0.00 and earned 333.76K in profits. Earnings per share was -1.80.
Revenue0.00
Gross Profit0.00
Operating Income-6.52M
Pretax Income333.76K
Net Income333.76K
EBITDA0.00
Earnings Per Share (EPS)-1.80
Cash Flow
In the last 12 months, operating cash flow was -2.27M and capital expenditures 0.00, giving a free cash flow of -2.27M billion.
Operating Cash Flow-2.27M
Free Cash Flow-2.27M
Free Cash Flow per Share-0.33
Dividends & Yields
PharmaCyte Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.94
52-Week Price Change-42.65%
50-Day Moving Average1.47
200-Day Moving Average1.68
Relative Strength Index (RSI)43.23
Average Volume (3m)15.07K
Important Dates
PharmaCyte Biotech upcoming earnings date is Mar 16, 2022, TBA Not Confirmed.
Last Earnings DateDec 15, 2021
Next Earnings DateMar 16, 2022
Ex-Dividend Date―
Financial Position
PharmaCyte Biotech as a current ratio of 6.80, with Debt / Equity ratio of 0.00%
Current Ratio6.80
Quick Ratio6.80
Debt to Market Cap0.00
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, PharmaCyte Biotech has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
PharmaCyte Biotech EV to EBITDA ratio is 0.00, with an EV/FCF ratio of 13.88.
EV to Sales0.00
EV to EBITDA0.00
EV to Free Cash Flow13.88
EV to Operating Cash Flow13.88
Balance Sheet
PharmaCyte Biotech has $16.76M in cash and marketable securities with $2.38M in debt, giving a net cash position of -$16.76M billion.
Cash & Marketable Securities$16.76M
Total Debt$2.38M
Net Cash-$16.76M
Net Cash Per Share-$2.44
Tangible Book Value Per Share$3.96
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for PharmaCyte Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―